Researchers at McGill University’s Rosalind & Morris Goodman Cancer Institute have developed a method to strengthen natural killer (NK) cells using small-molecule drugs. This reversible approach successfully attacked aggressive cancer cells in preclinical studies, offering a potentially safer and more affordable alternative to the permanent genetic engineering used in many current immunotherapies.
Reversing the Genetic Risk of Immunotherapy
Modern cancer treatments often rely on the permanent genetic modification of immune cells to help them recognize and destroy tumors. While these engineered cells can be highly effective, the permanent nature of the changes presents a significant clinical risk: if a patient experiences unintended or severe side effects, the modification cannot be easily undone.
A new strategy reported by sciencedaily.com suggests a different path. Instead of altering the DNA of the cells, scientists at the Research Institute of the McGill University Health Centre used small-molecule drugs to temporarily boost the activity of NK cells. By blocking two specific proteins, the team found they could make these cells “ready to attack” without making any lasting changes to their genetic structure.
Because this method is reversible, it provides a level of control that current genetic-based therapies lack. This capability could allow clinicians to adjust or even halt the treatment if adverse reactions occur, potentially making the therapy significantly safer for widespread use.
“This approach is particularly promising for patients who currently have very few options, when standard treatments have failed,”
Michel L. Tremblay, Distinguished James McGill Professor, via sciencedaily.com
Moving Toward “Off-the-Shelf” Cancer Treatments
Beyond the safety implications of reversible activation, the research addresses a massive logistical hurdle in oncology: the time and cost of cell production. Many existing immunotherapies require a process where a patient’s own immune cells are collected, customized in a lab, and then re-infused. This bespoke process can take weeks—a delay that many aggressive cancer patients simply do not have.
The McGill team has bypassed this requirement by utilizing NK cells derived from donated umbilical cord blood. These cells are isolated, cultured, and stored at the Cellular Therapy Laboratory, led by Pierre Laneuville and Linda Peltier. This allows for a much more scalable model of care.
As Chu-Han Feng, a research scientist at the Rosalind & Morris Goodman Cancer Institute, noted, the use of readily available drugs to enhance these cells avoids the complex customization process. This shift toward “off-the-shelf” availability could fundamentally change the economics of cancer care.
- Speed: These NK cells can be ready for use immediately upon a patient’s need.
- Affordability: Reducing the need for individualized manufacturing lowers the cost of treatment.
- Accessibility: A standardized cell supply makes it easier to deliver therapy across different medical centers.
Success Against High-Aggression Tumors
The efficacy of this supercharged approach has been demonstrated in preclinical models. In laboratory settings, the enhanced NK cells successfully destroyed human cancer cells from several highly aggressive and difficult-to-treat malignancies. The study also indicated that the treatment significantly slowed the growth of tumors in animal models.
- Leukemia
- Glioblastoma
- Kidney cancer
- Triple-negative breast cancer
While these results are currently limited to preclinical stages, they provide a foundation for developing next-generation treatments that are both more powerful and more controllable. As the research moves forward, the ability to use small-molecule drugs to toggle immune activity could turn what is currently a slow, expensive, and permanent procedure into a rapid and manageable medical intervention.
